Skip Navigation

Cardiovascular Research 2004 62(1):53-62; doi:10.1016/j.cardiores.2004.01.022
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Valdivia, C. R
Right arrow Articles by Ackerman, M. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valdivia, C. R
Right arrow Articles by Ackerman, M. J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs

Carmen R Valdiviaa,1, David J Testerb,1, Benjamin A Roka, Co-burn J Porterc, Thomas M Mungerd, Arshad Jahangird, Jonathan C Makielskia and Michael J Ackerman*,b,c,d

aDepartment of Medicine and Physiology, University of Wisconsin, Madison, WI, USA
bDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester MN, USA
cDepartment of Pediatrics/Division of Pediatric Cardiology, Mayo Clinic College of Medicine, Rochester MN, USA
dDepartment of Medicine/Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester MN, USA

* Corresponding author. Sudden Death Genomics Laboratory, Mayo Clinic College of Medicine, Guggenheim 501, 200 First Street SW, Rochester, MN 55905, USA. Tel.: +1-507-284-0101; fax: +1-507-284-3757. Email address: ackerman.michael{at}mayo.edu

Background: The human cardiac SCN5A gene encodes for the {alpha} subunit of the human cardiac voltage-dependent sodium channel hNav1.5 [Neuron 28 (2) (2000) 365] and carries inward Na current (INa). Mutations in SCN5A cause arrhythmia syndromes including Brugada syndrome (BrS) and congenital long QT syndrome subtype 3 (LQT3). Here, we report a trafficking defective BrS-causing SCN5A mutation that was drug-rescued.

Methods and Results: A 14-year-old Caucasian male was diagnosed with BrS with typical ECG pattern for BrS and ventricular fibrillation was easily induced. He also had significant HV interval delay (~65 ms) and high (31 J) defibrillation thresholds (DFTs). Genomic analysis revealed the SCN5A mutation (G1743R). We engineered G1743R into the cardiac Na channel and transfected HEK-293 cells for functional studies. The mutant channel yielded nearly undetectable sodium channel currents. Coexpression with the β1 subunit, or incubation at low temperature did not increase current density. However, mexiletine, a sodium channel blocker, increased current density 93-fold in G1743R, but only twofold in WT.

Conclusions: This study identifies an expression-defective BrS mutation in SCN5A with pharmacological rescue. The profoundly decreased sodium current associated with the G1743R suggests a molecular basis for the delayed His-Purkinje conduction and elevated DFTs observed in the proband. Whether the mutant channel may be rescued in vivo by mexiletine and normalize the patient's electrophysiologic parameters remains to be tested.

KEYWORDS Arrhythmia (mechanisms); Na-channel; Ion channels; Brugada syndrome; SCN5A; NaV1.5; Genetic testing

Abbreviations: SCN5A, official gene designation for the cardiac sodium channel gene residing on chromosome 3p21 • NaV1.5, nomenclature for the channel protein product of SCN5A • hH1c, cDNA clone used to construct the mutant channel for heterologous expression • WT, "wild-type" Na channel • G1743R, mutated SCN5A channel containing an arginine (R) at position 1743 instead of the normal glycine (G) residue


1 Contributed equally to this work.

Time for primary review 10 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. R. Valdivia, K. Ueda, M. J. Ackerman, and J. C. Makielski
GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A
Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1446 - H1452.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. Schulze-Bahr
Making sense in a nonsense reading frame: suppression of cardiac sodium channel dysfunction
Cardiovasc Res, August 1, 2009; 83(3): 423 - 424.
[Full Text] [PDF]


Home page
J. Neurosci.Home page
L. M. Sharkey, X. Cheng, V. Drews, D. A. Buchner, J. M. Jones, M. J. Justice, S. G. Waxman, S. D. Dib-Hajj, and M. H. Meisler
The ataxia3 Mutation in the N-Terminal Cytoplasmic Domain of Sodium Channel Nav1.6 Disrupts Intracellular Trafficking
J. Neurosci., March 4, 2009; 29(9): 2733 - 2741.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B.-H. Tan, P. Iturralde-Torres, A. Medeiros-Domingo, S. Nava, D. J. Tester, C. R. Valdivia, T. Tusie-Luna, M. J. Ackerman, and J. C. Makielski
A novel C-terminal truncation SCN5A mutation from a patient with sick sinus syndrome, conduction disorder and ventricular tachycardia
Cardiovasc Res, December 1, 2007; 76(3): 409 - 417.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. London, M. Michalec, H. Mehdi, X. Zhu, L. Kerchner, S. Sanyal, P. C. Viswanathan, A. E. Pfahnl, L. L. Shang, M. Madhusudanan, et al.
Mutation in Glycerol-3-Phosphate Dehydrogenase 1-Like Gene (GPD1-L) Decreases Cardiac Na+ Current and Causes Inherited Arrhythmias
Circulation, November 13, 2007; 116(20): 2260 - 2268.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. M. Cordeiro, H. Barajas-Martinez, K. Hong, E. Burashnikov, R. Pfeiffer, A.-M. Orsino, Y. S. Wu, D. Hu, J. Brugada, P. Brugada, et al.
Compound Heterozygous Mutations P336L and I1660V in the Human Cardiac Sodium Channel Associated With the Brugada Syndrome
Circulation, November 7, 2006; 114(19): 2026 - 2033.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
B.-H. Tan, C. R. Valdivia, C. Song, and J. C. Makielski
Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1822 - H1828.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. A. Camacho, S. Hensellek, J.-S. Rougier, S. Blechschmidt, H. Abriel, K. Benndorf, and T. Zimmer
Modulation of Nav1.5 Channel Function by an Alternatively Spliced Sequence in the DII/DIII Linker Region
J. Biol. Chem., April 7, 2006; 281(14): 9498 - 9506.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Liu, T. Yang, P. C. Viswanathan, and D. M. Roden
New Mechanism Contributing to Drug-Induced Arrhythmia: Rescue of a Misprocessed LQT3 Mutant
Circulation, November 22, 2005; 112(21): 3239 - 3246.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. I. Keller, J.-S. Rougier, J. P. Kucera, N. Benammar, V. Fressart, P. Guicheney, A. Madle, M. Fromer, J. Schlapfer, and H. Abriel
Brugada syndrome and fever: Genetic and molecular characterization of patients carrying SCN5A mutations
Cardiovasc Res, August 15, 2005; 67(3): 510 - 519.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.